Previous Close | 13.90 |
Open | 13.96 |
Bid | 14.50 x 900 |
Ask | 14.55 x 4000 |
Day's Range | 13.87 - 14.52 |
52 Week Range | 11.25 - 129.70 |
Volume | |
Avg. Volume | 11,925,703 |
Market Cap | 4.458B |
Beta (5Y Monthly) | 1.25 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.04 |
Earnings Date | Aug 24, 2022 - Aug 29, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.57 |
Subscribe to Yahoo Finance Plus to view Fair Value for PTON
Two such stocks that could struggle for a long time to come are Ocugen (NASDAQ: OCGN) and Peloton Interactive (NASDAQ: PTON). Up until now, it has had nothing to show for its agreement with Bharat Biotech to help commercialize the Indian-based company's COVID-19 vaccine, Covaxin. Its agreements were to share in the profits of the vaccine in the Canadian and U.S. markets -- but Covaxin isn't approved for use in either country.
'Demand is softening, cost inflation increasing, and competitive headwinds intensifying,' said a Craig-Hallum analyst on the at-home fitness industry.
On a day that the stock market is up over 1% overall, we have seen shares of Peloton Interactive (NASDAQ: PTON) drop as much as 10%. The market continues to try to figure out what to do with a potential U.S. recession, rising interest rates, and a shift away from pandemic stocks. Today's loudest voice was the Financial Times, which highlighted that Peloton actually has an inventory problem on its hands now that demand for bikes and treadmills has fallen.